海思科(002653.SZ)：获得创新药HSK39297片上市许可《受理通知书》

Core Viewpoint - The company announced that its subsidiary, Sichuan Hisun Pharmaceutical Co., Ltd., received a Notice of Acceptance from the National Medical Products Administration for its drug HSK39297, a selective complement factor B inhibitor aimed at treating diseases mediated by abnormal complement activation [1] Group 1 - HSK39297 is a self-developed small molecule inhibitor that effectively inhibits the activity of complement factor B, blocking the activation of the alternative pathway and the complement amplification cycle [1] - The drug is designed to control both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [1] - HSK39297 acts at the proximal end of the complement cascade's alternative pathway, targeting the mechanisms that lead to hemolysis [1]